Drug Trial Radar · NCT04578028
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Aug 19, 2020
Primary completion
Aug 26, 2021
Study completion Oct 7, 2021
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants. The study will be conducted in 3 parts: Part A, a single-ascending dose part with an assessment of the potential food effects in non-Japanese adult participants; Part B, a single dose part to assess the effect of age in non-Japanese elderly participants; and Part C, a multiple-ascending dose part with ONO-2808 administered to healthy subjects.
Conditions
- Neurodegenerative Diseases
Interventions
ONO-2808Drug
Investigational drug
PlaceboDrug
Placebo drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events (TEAEs) by severity.Time frame: Part A and B: up to day 7; Part C: up to 17 days.
- Serious adverse events (SAEs)Time frame: Part A and B: up to day 7; Part C: up to 17 days.
- Vital signsTime frame: Part A and B: up to day 7; Part C: up to 17 days
- ECG parametersTime frame: Part A and B: up to day 7; Part C: up to 17 days.
- Clinical laboratory testsTime frame: Part A and B: up to day 7; Part C: up to 17 days
- Physical examinationTime frame: Part A and B: up to day 7; Part C: up to 17 days
- Neurological examinationTime frame: Part A and B: up to day 7; Part C: up to 17 days.
- Number of participants with suicidal behaviourTime frame: Part C: up to 17 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International Early Phase Clinical Unit (EPCU)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.